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Background: Ginsenosides, the major bioactive compounds in ginseng root, have been found to have antioxidant,
immunomodulatory and anti-inflammatory activities. This study investigated the effects of ginsenosides on carbon
tetrachloride (CCl4)-induced hepatitis and liver fibrosis in rats.
Methods: Male Sprague–Dawley rats were randomly divided into four groups: control, CCl4, CCl4 + 0.5 g/kg Panax
ginseng extract and CCl4 + 0.05 g/kg ginsenoside Rb1 groups. The treated groups were orally given Panax ginseng
extract or ginsenoside Rb1 two weeks before the induction of liver injury for successive 9 weeks. Liver injury was
induced by intraperitoneally injected with 400 ml/l CCl4 at a dose of 0.75 ml/kg body weight weekly for 7 weeks.
The control group was intraperitoneally injected with olive oil.
Results: The pathological results showed that ginsenoside Rb1 decreased hepatic fat deposition (2.65 ± 0.82 vs 3.50
± 0.75, p <0.05) and Panax ginseng extract lowered hepatic reticular fiber accumulation (1.05 ± 0.44 vs 1.60 ± 0.39, p
<0.01) increased by CCl4. Plasma alanine aminotransferase and aspartate aminotransferase activities were increased
by CCl4 (p <0.01), and aspartate aminotransferase activity was decreased by Panax ginseng extract at week 9 (p <0.05).
Exposure to CCl4 for 7 weeks, the levels of plasma and hepatic triglycerides (p <0.01), hepatic cholesterol (p <0.01),
interleukin-1β (p <0.01), prostaglandin E2 (p <0.05), soluble intercellular adhesion molecule-1 (p <0.05), hydroxyproline
(p <0.05), matrix metalloproteinase-2 (p <0.05) and tissue inhibitor of metalloproteinase-1 (TIMP-1) (p <0.01) were
elevated, however, hepatic interleukin-10 level was lowered (p <0.05). Both Panax ginseng extract and ginsenoside
Rb1 decreased plasma and hepatic triglyceride, hepatic prostaglandin E2, hydroxyproline and TIMP-1 levels, and Panax
ginseng extract further inhibited interleukin-1β concentrations (p <0.05).
Conclusions: Panax ginseng extract and ginsenoside Rb1 attenuate plasma aminotransferase activities and liver
inflammation to inhibit CCl4-induced liver fibrosis through down-regulation of hepatic prostaglandin E2 and TIMP-1.
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Liver cirrhosis is an irreversible stage in the process of
liver damage that occurs after liver fibrosis. Liver fibrosis
is attributed to inflammation, excessive accumulation of
extracellular matrix and tissue remodeling under wound
healing [1]. Chronic hepatitis and liver cirrhosis are posi-
tively associated with the occurrence of hepatocellular
carcinoma [2,3]. Therefore, the inhibition of hepatic* Correspondence: chenjui@tmu.edu.tw
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occurrence of liver cirrhosis and hepatocellular carcinoma.
Oxidative stress from reactive oxygen species plays an
important role in liver fibrogenesis [4]. Carbon tetrachlor-
ide (CCl4) is considered as a toxic chemical that induces
hepatotoxicity including fatty degeneration, inflammation,
fibrosis, hepatocellular death and carcinogenicity [5,6].
Trichloromethyl radical produced from the metabol-
ism of CCl4 initiates a chain reaction to cause lipid
peroxidation, membrane dysfunction and further hepato-
toxic damage [6]. The toxic metabolite of CCl4 can activate
Kupffer cells to secrete cytokines such as interleukin-1
(IL-1) and tumor necrosis factor-α (TNF-α), stimulate
transforming growth factor-β (TGF-β) production, inhibit. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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liver fibrosis [6-8]. Matrix metalloproteinase (MMP)-2,
known as type IV collagenase and gelatinase A, acts as the
regulator for the breakdown of extracellular matrix, and
tissue inhibitor metalloproteinase (TIMP)-1, as the inhibi-
tor of MMPs, exhibits anti-fibrolytic, growth-stimulated
and anti-apoptotic activities [9]. Chronic exposure of CCl4
leads to liver fibrosis, which diminishes extracellular matrix
degradation and increases MMP-2 secretion through the
induction of tissue inhibitor TIMPs [9].
Panax ginseng (P. ginseng) root has been commonly
used in oriental medicine, diet or dietary supplement.
Ginsenosides, a class of steroid glycosides and triterpene
saponins, are the major bioactive compounds in P. ginseng
root and ginsenoside Rb1 (C54H92O23, molecular weight:
1109.3) is considered as the most abundant ginsenoside
among more than 30 ginsenosides in P. ginseng [10,11].
The previous studies have reported that P. ginseng and its
active components or metabolites had antioxidant, immu-
nomodulatory, anti-inflammatory, and lipid-lowering ef-
fects [12-15]. Many studies have shown that ginsenoside
Rb1 and its metabolite compound K attenuated liver
injury through inhibiting lipid peroxidation, TNF-α,
NO, prostaglandin E2 (PGE2), intercellular adhesion
molecule (ICAM)-1 and nuclear factor-κB (NF-κB) ac-
tivation [16-19]. However, the effect of ginsenosides on
liver fibrosis is not clear. Considering ginsenoside Rb1
as the most abundant ginsenoside in P. ginseng [10,11]
and its hepatoprotective activity [16-19], therefore, this
study investigated the protective effects of P. ginseng
extract (ginseng extract) and ginsenoside Rb1 on CCl4-
induced liver inflammation and fibrosis in rats.
Methods
Animals and treatments
Sprague–Dawley rats weighing 200–250 g were purchased
from the National Laboratory Animal Center (Taipei,
Taiwan). Rats were housed under a 12-h light–dark
cycle at 22-24°C with a relative humidity of 65-70%.
After one-week adaptation, rats were randomly divided
into four groups (n =10 per group): control, CCl4, CCl4 +
ginseng extract (GE) and CCl4 + ginsenoside Rb1 (Rb1)
groups. The normal diet based on Laboratory Rodent
Diet 5001 powder was purchased from PMI Nutrition
International Inc. (Brentwood, MO). Ginseng extract
(Ashland Inc., Covington, KY, USA) containing 800 g
ginsenosides/kg extract (80%) (ginsenosides in the extract
include Rb1, Rc, Rd, Rg1, Rg2, Rg3, Rh1 and Rh2) and
ginsenoside Rb1 (China Chemical & Pharmaceutical Co.,
Ltd., Taipei, Taiwan) with 98% purity were blended with
the normal diet at a dose of 0.5 g/kg and 0.05 g/kg, re-
spectively. Ginsenoside Rb1 content was equal in the GE
and Rb1 groups. Rats were fed ginseng extract or gin-
senoside Rb1 two weeks before (week 0, W0) theinduction of liver injury by intraperitoneal injection of
400 ml/l CCl4 in olive oil at a dose of 0.75 ml/kg body
weight weekly for 7 weeks. The control group was
injected with an equal volume of olive oil without
CCl4. Food intake, water intake and body weight were
recorded throughout 9-week experimental period. This
study was approved by the Institutional Animal Care
and Use Committee of Taipei Medical University.
Histopathological examination
After 9 weeks, rats were euthanized with ether and liver
samples from left lateral lobe, median lobe and right
lateral lobe were collected for histopathological and
biochemical analyses. Excised liver specimens from dif-
ferent lobes (1 cm × 1 cm) were fixed in 10% paraformal-
dehyde, embedded in paraffin, sectioned and stained with
hematoxylin and eosin (H&E), Masson’s trichrome or
silver. The specimens were coded with a single-blind
method and graded from 0 (no lesion), 1 (trace lesion),
2 (weak lesion), 3 (moderate lesion) to 4 (severe lesion)
for fat changes, and from 0 (no lesion), 1 (lesion in the
central vein area), 2 (lesion in the central vein area and
expansion to the surrounding area) to 3 (lesion in the
central and portal vein areas or cirrhosis) for necrosis,
inflammation, and fibrosis under a light microscope by
a pathologist.
Plasma alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) activities
Blood samples from rat tails were collected into heparin-
containing tubes at weeks 0, 2 (CCl4 injection) and 9.
Blood was centrifuged at 3000 g for 15 min at 4°C.
Plasma ALT and AST activities were measured spectro-
photometrically at 570 nm using a commercial kit (RM
163-K, Iatron Laboratories Inc., Tokyo, Japan).
Plasma and hepatic lipid concentrations
Blood samples from rat tails were collected at weeks 0, 2
and 9, and centrifuged at 3000 g for 15 min at 4°C. Liver
samples from left lateral lobe, median lobe and right lat-
eral lobe were homogenized in chloroform/methanol
(2:1) solution and extracted by chloroform/methanol/
water (3:48:47) solution. Triglycerides and total choles-
terol concentrations in plasma and liver were determined
spectrophotometrically at 500 nm using commercial en-
zymatic kits (Randox® TR213 for triglycerides, Randox®
CH201 for total cholesterol, Randox Laboratories Ltd.,
London, UK).
Hepatic inflammatory markers
Liver slices (0.5 g) were homogenized in 1.5 mL of buffer
solution (50 mmol/l Tris, 150 mmol/l NaCl, and 10 ml/l
Triton X-100, pH 7.2) [20] and mixed with 100 μl of pro-
teinase inhibitor cocktail solution (P8340, Sigma-Aldrich,
Table 1 Body weight, liver weight and food intake in rats
treated with ginsenosides against CCl4-induced liver
damage
Control CCl4 GE Rb1
Initial body weight (g) 240 ± 8a 233 ± 12a 236 ± 14a 239 ± 15a
Final body weight (g) 478 ± 23b 427 ± 25a 433 ± 38a 448 ± 37a
Weight gain (g) 238 ± 22b 194 ± 23a 208 ± 34a 209 ± 30a
Total liver weight (g) 15.9 ± 2.5a 17.5 ± 1.5a 17.3 ± 3.8a 16.4 ± 1.8a
Relative liver
weight (g/kg)
33.2 ± 4.8a 41.1 ± 3.4c 39.7 ± 5.8bc 36.7 ± 3.4ab
Food intake (g/d) 26.5 ± 1.6a 25.3 ± 1.0a 25.2 ± 1.2a 25.4 ± 1.2a
Data are presented as mean ± SD (n =10). Values not sharing the same
superscript differ significantly (p <0.05) within the same row.
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at 3000 g for 15 min at 4°C for TNF-α, IL-1β and IL-10
analysis. For PGE2 and soluble ICAM-1 (sICAM-1) ana-
lysis, liver slices (0.5 g) were mixed with 1.0 ml of homog-
enized buffer (0.25 mol/l sucrose, 50 mmol/l Tris–HCl,
and 5 mmol/l EDTA, pH 7.5). Liver homogenate was cen-
trifuged at 8000 g for 15 min at 4°C.
Hepatic TNF-α, IL-1β, IL-10, PGE2 and sICAM-1 levels
were measured spectrophotometrically using enzyme-
linked immunosorbent assay (ELISA) kits (Quantikine®
RTA00 for TNF-α, Quantikine® RLB00 for IL-1β, DuoSet®
DY522 for IL-10, PGE2, Quantikine® KGE004 for PGE2,
Quantikine® RIC100 for sICAM-1, R&D Systems, Inc.,
Minneapolis, USA). Hepatic supernatant was separately
incubated with rat anti-TNF-α, anti-IL-1β, anti-IL-10,
anti-PGE2 or anti-sICAM-1, then washed with wash
buffer (0.05% Tween® in phosphate buffer solution, PBS)
followed by incubation with polyclonal antibody against
TNF-α, IL-1β, PGE2 or sICAM-1 conjugated to horse-
radish peroxidase or biotinylated anti-IL-10 secondary
antibody with streptavidin conjugated to horseradish
peroxidase, respectively. After washed with wash buffer
several times, the substrate solution (hydrogen perox-
ide and chromogen tetramethylbenzidine) was added
and the reaction was terminated by adding diluted
hydrochloric acid. The absorbance was determined at
450 nm. Protein concentration was measured by the
method of Lowry et al. [21].
Hepatic hydroxyproline, MMP-2 and TIMP-1 levels
Hepatic hydroxyproline level was measured by colorimet-
ric assay. Freeze-dried liver specimen (0.25 g) was homog-
enized with 2 ml of distilled water. Liver homogenate was
hydrolyzed in alkaline solution (2 mol/L NaOH), oxidized
with chloramines T reagent, and incubated with Ehrlich’s
reagent at 65°C. The chromogenic product was deter-
mined spectrophotometrically at 550 nm.
The levels of MMP-2 and TIMP-1 in the liver were de-
termined by commercial kits (Quantikine® DMP200 for
MMP-2, Quantikine® RTM100 TIMP-1, R&D Systems,
Inc.) using ELISA. Liver slices were homogenized with
PBS and proteinase inhibitor cocktail solution and centri-
fuged at 12000 g for 10 min at 4°C. The supernatant was
centrifuged again and collected for further analysis.
Hepatic supernatant was separately incubated with rat
anti-MMP-2 or anti- TIMP-1, washed with wash buf-
fer, and incubated with polyclonal antibody against
MMP-2 or TIMP-1 conjugated to horseradish peroxid-
ase followed by several washes with wash buffer. The
substrate solution (hydrogen peroxide and chromogen
tetramethylbenzidine) was added for the reaction and
stop solution (diluted hydrochloric acid) was then added
to stop the reaction. The absorbance was measured at
450 nm.Statistical analysis
All data were expressed as mean ± SD. The data were
analyzed by one-way analysis of variance (ANOVA)
using Statistical Analysis System (SAS version 9.1, SAS
Institute Inc., Cary, NC, USA). The difference between
any two groups was analyzed by Fisher’s least significant
difference test. A value p <0.05 was considered significant.
Results
Body weight, liver weight and food intake
The results of body weight, liver weight and food intake
were shown in Table 1 to monitor the effects of the
treatments on gross growth and liver weight. Final
body weight and weight gain were significantly higher
in the control group than those in the CCl4 (p <0.01),
GE (p <0.05), and Rb1 (p <0.05) groups (Table 1), but
not significantly different among the three CCl4 treated
groups. Daily intake of ginseng extract and ginsenoside
Rb1 was 12.6 ± 0.6 mg (33.8 ± 1.5 mg/kg body weight) and
1.3 ± 0.6 mg (3.3 ± 0.1 mg/kg body weight) in the GE and
Rb1 groups, respectively. The relative liver weight was sig-
nificantly higher in the CCl4 and GE groups than that in
the control group (p <0.01). The Rb1 group significantly
reduced the relative liver weight compared with the CCl4
group (p <0.05). However, total liver weight and daily food
intake did not differ significantly among the four groups.
Histopathological examination
The results of the histopathological examination by dif-
ferent stains were demonstrated in Figures 1 and 2 to
determine the effects of the treatments on histopatho-
logical changes in the liver, especially on liver fibrosis.
The bright red color of H&E staining shown in Figure 1A
could be resulted from strong eosin staining, a fluores-
cent red dye. The pathological sections stained by H&E
showed that no fat was accumulated in the liver of the
control group, whereas large fat vacuoles were observed
in the liver of the CCl4 group (Figure 1A). However, the
Rb1 group had significantly decreased fat vacuoles
Figure 1 The representative histological sections of rat liver specimens. A: hematoxylin and eosin stain at 20 × 10 magnification, B: semi-quantitative
scores graded from 0 (no lesion), 1 (trace lesion), 2 (weak lesion), 3 (moderate lesion) to 4 (severe lesion) for fat changes, and from 0 (no lesion), 1 (lesion in
the central vein area), 2 (lesion in the central vein area and expansion to the surrounding area) to 3 (lesion in the central and portal vein areas or cirrhosis) for
necrosis, inflammation and fibrosis in control, CCl4, GE and Rb1 groups. Solid and dashed arrows represent the central vein and collagen fibers. Data
are presented as mean ± SD (n =10). Values not sharing the same letter differ significantly (p <0.05). Scale bar =50 μm.
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p <0.05) (Figure 1B). The pathological scores for fat change
were not significantly different between the GE and Rb1
groups. The CCl4, GE, and Rb1 groups had significantly el-
evated cell necrosis (p <0.05), inflammatory cells (p <0.01),
and fibrosis (p <0.01) in the central veins compared with
the control group. However, the pathological scores for ne-
crosis, inflammation, and fibrosis in the liver did not signifi-
cantly differ among the three CCl4 treated groups.The pathological assessment of liver fibrosis as ob-
served by Masson’s trichrome stain demonstrated that
the formation of collagen fibers appeared blue was ele-
vated by the exposure to CCl4 (Figure 2A). The fibrosis
scores determined by Masson’s trichrome stain in the
CCl4 (1.35 ± 0.34), GE (1.10 ± 0.39) and Rb1 (1.40 ± 0.39)
groups were significantly higher compared with the con-
trol group (p <0.01) (Figure 2C), but the GE group had a
lower liver fibrosis score compared with the Rb1 group
Figure 2 (See legend on next page.)
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Figure 2 The representative histological sections of rat liver specimens. A: Masson’s trichrome stain at 15 × 10 magnification, B: silver stain
at 15 × 10 magnification; C: semi-quantitative scores graded from 0 (no collagen formation), 1 (collagen formation in the central vein area), 2 (collagen
and fibrous bridge formation in different central vein areas) to 3 (cirrhosis) for fibrosis in the control, CCl4, GE and Rb1 groups. Collagen fibers stained with
Masson’s trichrome appear blue. Reticular fibers stained with silver appear brown. Solid and dashed arrows represent the central vein and fiber bridging.
Data are presented as mean ± SD (n =10). Values not sharing the same letter differ significantly (p <0.05). Scale bar =50 μm.
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stained by silver and appeared brown was increased by
the exposure to CCl4 (p <0.01) (Figure 2B). The GE
(1.05 ± 0.44) group had significantly reduced accumula-
tion of reticular fibers than the CCl4 (1.60 ± 0.39, p <0.01)
and Rb1 (1.40 ± 0.21, p <0.05) groups (Figure 2C).Plasma ALT and AST activities
Plasma ALT and AST activities were measured to assess
the effects of the treatments on liver functions. Plasma
ALT and AST activities were significantly elevated in the
CCl4 group than those in the control, GE and Rb1
groups (p <0.01) after the induction of liver injury (W2)
(Table 2). The CCl4 group still had increased plasma
ALT (p <0.05) and AST (p <0.01) activities compared with
the control group, whereas plasma ALT and AST activities
did not differ among the control, GE and Rb1 groups
at week 9. The GE group significantly decreased plasma
AST activity compared with the CCl4 group at week 9
(p <0.05).Plasma and hepatic triglyceride and total cholesterol
concentrations
Plasma and hepatic lipid concentrations were deter-
mined to evaluate the effects of the treatments on lipid
profiles. After the induction of liver injury (W2), plasma
triglycerides were significantly increased and still main-
tained higher level at week 9 in the CCl4 group com-
pared with those in the control group (p <0.01)
(Table 3). Treatment with GE (p <0.01) and Rb1 (p <0.05)
significantly reduced plasma triglycerides compared with
the CCl4 group to the similar level of the control group at
weeks 2 and 9.Table 2 Plasma ALT and AST activities in rats treated with gin
Control CCl4
ALT activity (IU/l)
W0 29.6 ± 2.9a 27.6 ± 1.7a
W2 33.2 ± 3.6a 4012.4 ± 22
W9 33.6 ± 4.9a 334.9 ± 379
AST activity (IU/l)
W0 75.9 ± 6.3a 78.3 ± 4.4a
W2 62.1 ± 20.2a 8370.4 ± 53
W9 63.3 ± 6.0a 288.4 ± 181
Data are presented as mean ± SD (n =10). Values not sharing the same superscriptAt the baseline, plasma total cholesterol level was sig-
nificantly lower in the CCl4 and Rb1 groups than that in
the control group (p <0.01). After the induction of liver
injury, total cholesterol level was significantly elevated in
the CCl4 group than that in the control and Rb1 groups
(p <0.05) (Table 3). Plasma total cholesterol level did not
differ significantly among the four groups at week 9.
Hepatic triglyceride concentrations were significantly
increased by 73% in the CCl4 group than those in the
control group (p <0.01), and decreased by 56% and 60%
in the GE and Rb1 groups, respectively, compared with
the CCl4 group (p <0.01) (Figure 3A). Hepatic total chol-
esterol level was significantly greater in the CCl4, GE and
Rb1 groups than that in the control group (p <0.01),
but not significantly different among CCl4 treated groups
(Figure 3B).
Hepatic TNF-α, IL-1β, IL-10, PGE2, and sICAM-1 levels
The results of hepatic cytokine levels were found in
Table 4 to determine the effects of the treatments on
hepatic mediators released in the inflammatory condition.
Hepatic IL-1β (p <0.01), PGE2 (p <0.05) and sICAM-1
(p <0.05) levels were significantly elevated, whereas
hepatic IL-10 level was significantly decreased in the
CCl4 group compared with those in the control group
(Table 4). Hepatic TNF-α, IL-1β and PGE2 levels were
significantly reduced in the GE group compared with
the CCl4 group (p <0.05). The Rb1 group had higher
hepatic TNF-α level than the GE group, but lower hep-
atic PGE2 level than the CCl4 group (p <0.05).
Hepatic hydroxyproline, MMP-2 and TIMP-1 levels
The results of hepatic hydroxyproline, MMP-2 and
TIMP-1 levels were shown in Figure 4 to investigate thesenosides
GE Rb1
31.2 ± 3.8a 29.2 ± 32.8a
12.9b 469.0 ± 435.2a 1072.6 ± 618.6a
.1b 136.4 ± 167.4ab 177.5 ± 333.0ab
70.8 ± 23.5a 77.6 ± 5.3a
60.8b 2155.0 ± 1973.8a 1233.6 ± 616.7a
.3b 134.9 ± 114.6a 171.3 ± 227.9a
differ significantly (p <0.05) within the same row.
Table 3 Plasma triglycerides and total cholesterol
concentrations in rats treated with ginsenosides
Control CCl4 GE Rb1
Triglycerides
(mmol/l)
W0 0.16 ± 0.04a 0.16 ± 0.04a 0.14 ± 0.03a 0.15 ± 0.02a
W2 0.24 ± 0.04a 0.39 ± 0.19b 0.25 ± 0.04a 0.28 ± 0.10a
W9 0.54 ± 0.10c 0.35 ± 0.06b 0.27 ± 0.05a 0.29 ± 0.07a
Total cholesterol
(mmol/l)
W0 0.90 ± 0.11b 0.71 ± 0.12a 0.79 ± 0.16ab 0.75 ± 0.10a
W2 1.01 ± 0.14a 1.20 ± 0.18b 1.05 ± 0.21ab 0.95 ± 0.27a
W9 0.79 ± 0.11a 0.70 ± 0.17a 0.67 ± 0.10a 0.66 ± 0.20a
Data are presented as mean ± SD (n =10). Values not sharing the same
superscript differ significantly (p <0.05) within the same row.
Figure 3 Effects of ginsenosides extract and ginsenoside Rb1 on hep
concentration. Data are presented as mean ± SD (n =10). Values not sharin
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sis. Hepatic hydroxyproline (p <0.05), MMP-2 (p <0.05)
and TIMP-1 (p <0.01) levels were elevated by 55%, 28%
and 61%, respectively, in the CCl4 group compared with
the control group (Figure 4). Ginseng extract and ginseno-
side Rb1 treatments significantly reduced hepatic hydroxy-
proline level by 36% and 30% (Figure 4A) and TIMP-1
level by 27% and 27% (Figure 4C), respectively, compared
with the CCl4 group (p <0.05). However, hepatic MMP-2
level was not different in the three CCl4 treated groups
(Figure 4B).
Discussion
Similar to the previous study [22], plasma ALT and AST
activities were increased by CCl4-induced liver injury.
Ginseng extract and ginsenoside Rb1 significantly de-
creased plasma ALT and AST activities elevated by the
exposure to CCl4. The previous studies demonstrated
that ginseng extract or heated ginseng exhibited antioxi-
dant activity and acted as a free radical scavenger to in-
hibit lipid peroxidation in vitro and increase catalase andatic lipids in rats. A: hepatic triglycerides, B: total cholesterol
g the same letter differ significantly (p <0.05).
Table 4 Hepatic TNF-α, IL-1β, IL-10, PGE2, and sICAM-1 levels in rats treated with ginsenosides
Control CCl4 GE Rb1
TNF-α (pg/mg protein) 15.8 ± 7.6ab 17.2 ± 5.1b 10.4 ± 3.3a 16.7 ± 6.9b
IL-1β (pg/mg protein) 132.5 ± 39.6a 333.0 ± 135.8c 212.0 ± 115.2ab 292.9 ± 182.9bc
IL-10 (pg/mg protein) 4461 ± 958b 3443 ± 508a 3513 ± 677a 3514 ± 600a
PGE2 (pg/mg protein) 6196 ± 1599
b 9822 ± 2610c 4636 ± 1928ab 4128 ± 1480a
sICAM-1 (pg/mg protein) 2782 ± 771a 3991 ± 867b 3288 ± 567ab 3427 ± 963ab
Data are presented as mean ± SD (n =10). Values not sharing the same superscript differ significantly (p <0.05) within the same row.
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cells [14,23]. Moreover, ginsenoside Rb1, Rg1 or derived
metabolite-compound K decreased hepatic malondialde-
hyde level and increased serum ALT and AST activities
[16,18]. Therefore, ginseng extract and ginsenoside Rb1,
as a free radical scavenger, may eliminate free radical
damage to the hepatocytes.
Exposure to CCl4 led to significant increases in the ac-
cumulation of fat vacuoles and the levels of triglycerides
and total cholesterol in the liver. The abnormal fat accu-
mulation in the liver caused by CCl4 could be attributed
to: (1) the imbalance between lipogenesis and lipolysis
by increasing lipid synthesis and the rate of lipid esterifi-
cation [24] as well as by decreasing cAMP production
via the stimulation of hormone-sensitive lipase [25,26],
and (2) impaired synthesis and secretion of very low
density lipoprotein through the interference of glycosyla-
tion and maturation of lipoglycoprotein by free radicals
which are produced by CCl4 metabolism [24,27], or
through the inactivation of Ca+2-ATPase pump in the
mitochondria and endoplasmic reticulum [6,28].
Liver damage and elevated hepatic triglycerides in-
duced by CCl4 were improved by the treatment of GE
and Rb1. Red ginseng saponin, containing ginsenosides
Rb1, Rb2, Rc, Rd, Re and Rg1, played a crucial role in
hepatoprotection by suppressing oxidative stress and
lipid peroxides via inhibiting the expression and activity
of cytochrome P450 in the liver [29]. Consistent with
our findings, ginsenoside Rb1 injected intraperitoneally
at a dose of 10 mg/kg body weight for 3 d significantly
decreased hepatic lipids by increasing hepatic cAMP
production [30]. Additionally, Rb1 injected intraperito-
neally at a dose of 10 mg/kg body weight also showed to
reduce hepatic triglyceride accumulation in high fat diet-
induced obese rats by increasing hepatic carnitine palmi-
toyltransferase 1 activity and cellular AMP/ATP ratio to
stimulate fatty acid oxidation and suppress lipogenesis,
respectively [31]. Compound K, a major intestinal metabol-
ite of ginsenosides, has been demonstrated to elevate gene
expression of peroxisome proliferator-activated receptor-α
and decrease gene expression of fatty acid synthase
and stearoyl-CoA desaturase 1 through activating AMP-
activated protein kinase in HepG2 human hepatoma cells[32]. The previous study revealed that ginseng extract rich
in ginsenosides suppressed hepatic cholesterol synthesis
via inhibiting hepatic β-hydroxy-β-methylglutaryl-CoA re-
ductase and cholesterol 7α-hydroxylase activities [33].
These results suggest that ginseng extract, ginsenoside
Rb1 and their metabolite may accelerate lipid utilization
and suppress lipid biosynthesis in the liver to further de-
crease elevated hepatic triglycerides induced by CCl4
exposure.
Kupffer cells activated by oxidative stress secrete cyto-
kines, such as TNF-α and IL-1β, to stimulate the expression
of sICAM-1 which induces the activation of neutrophils
[7]. The results of H&E staining showed accumulation of
inflammatory cells in the CCl4 group. Furthermore, fibrotic
bridges were observed in the histopathological sections
stained by silver in the CCl4 group as cells became necrotic
and reticular fibers resembled after frameworks collapsed.
Ginseng extract reduced accumulation of reticular fibers,
ameliorated cell necrosis and inhibited production of TNF-
α and IL-1β. In agreement with our present study, in vitro
studies demonstrated that ginseng and ginsenoside Rb1
suppressed TNF-α production and IL-1β mRNA expres-
sion in murine RAW264.7 macrophages [34,35]. Ginseno-
side Rg1, one of the important components in P. ginseng,
intravenously injected at 20 mg/kg body weight signifi-
cantly attenuated serum TNF-α and IL-6 release in septic
mice [36].
The expression of PGE2 and cycloogenase-2 (COX-2)
are induced by inflammatory response, and the expres-
sion of COX-2 was stimulated by proinflammatory cyto-
kines, such as TNF-α and IL-1β [37]. Our present study
found that ginseng extract and ginsenoside Rb1 significantly
decreased hepatic PGE2 level induced by CCl4. It is pre-
sumed that ginseng extract and ginsenoside Rb suppressed
PGE2 production through reducing proinflammatory cyto-
kines and suppressing COX-2 expression. Furthermore, acti-
vation of NF-κB modulates expression and secretion of
proinflammatory cytokines, chemokines, adhesion mole-
cules, COX-2 and inducible nitric oxide synthase (iNOS)
[38]. Ginsenoside Rb1, Rg1, Rg3, Rh1 and their derived
metabolite compound K down-regulated activation of
NF-κB and simultaneously suppressed PGE2, ICAM-1,
COX-2 and iNOS expression in vitro [17,19,39-42]. It
Figure 4 Effects of ginsenosides extract and ginsenoside Rb1 on liver fibrosis markers in rats. A: hepatic hydroxyproline level, B: MMP-2
level; C: TIMP-1 level. Data are presented as mean ± SD (n =10). Values not sharing the same letter differ significantly (p <0.05).
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attenuated production of proinflammatory factors pos-
sibly via inhibiting NF-κB activation.
The accumulation of hydroxyproline and collagen fibers
was found in the CCl4 group, whereas ginseng extract and
ginsenoside Rb1 decreased hepatic hydroxyproline and
TIMP-1 levels to inhibit liver fibrosis. Oxidative stress in-
duced by CCl4 metabolism could further stimulate prolif-
eration and invasiveness of hepatic stellate cells (HSCs)
[43]. Proliferated HSCs resulted in increases in TGF-β1
secretion, which activates HSCs and induces gene expres-
sion of type I collagen, and induction of collagen accumu-
lation. Activated HSCs express MMPs and their tissue
inhibitors (TIMPs). Oxidative stress stimulated MMP-2
production by HSCs via extracellular signal-regulated kin-
ase1/2 and phosphatidylinositol 3 kinase pathways [43],
and MMPs induce HSCs proliferation and migration [44].
In vitro studies found that ginsenoside Rb1 inhibited
HSCs activation and mRNA expression of type I and III
collagen, TGF-β1 and TIMP-1 [45], and its metabolite in-
duced apoptosis in HSCs via caspase-3 activation pathway
[46]. Compound K was found to inhibit MMP-2 expres-
sion and NF-κB activation in the in vitro model [47]. Gin-
senoside Rg1 subcutaneously injected at 50 and 100 mg/
kg body weight attenuated serum levels of hyaluronic acid
and type III procollagen, and hepatic hydroxyproline level
in rats with thioacetamide-induced liver fibrosis [48]. The
decrease in activated HSCs could lead to inhibition of
fibrogenesis and TIMP-1 expression by reducing TNF-α
and TGF-β1 [49]. Our finding demonstrated that ginseng
extract and ginsenoside Rb1 diminished hepatic TIMP-1
level accompanied with decreased TNF-α level. Therefore,
ginseng extract and ginsenoside Rb1 could suppress acti-
vation and proliferation of HSCs and further inhibit liver
fibrosis.
Ginsenoside Rb1 content was equivalent in the GE
and Rb1 groups in the present study. Ginseng extract
with additional seven ginsenosides except for ginseno-
side Rb1 more effectively diminished collagen accumula-
tion and inhibited TNF-α production compared with
ginsenoside Rb1. Therefore, the hepatoprotective and
anti-inflammatory actions of ginseng extract on CCl4-
induced liver damage could be attributed to the synergis-
tic action of overall ingredients including the remaining
20% constituents and their metabolites.
Conclusions
In conclusion, Panax ginseng extract (0.5 g/kg) and gin-
senoside Rb1 (0.05 g/kg) decrease plasma ALT and AST
activities elevated by CCl4-induced liver damage and in-
hibit the accumulation of triglycerides in the liver. The
levels of TNF-α, PGE2, hydroxyproline and TIMP-1 in
the liver are diminished by ginseng extract and ginse-
noside Rb1. Therefore, ginseng extract and ginsenosideRb1 attenuate CCl4-induced liver injury through anti-
inflammatory and antifibrotic effects.
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